Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyridoxamine - NephroGenex/Kowa

Drug Profile

Pyridoxamine - NephroGenex/Kowa

Alternative Names: BST-4001; K-163; K163SZ; Pyridorin; Pyridoxamine dihydrochloride; Pyridoxamine hydrochloride

Latest Information Update: 06 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioStratum
  • Developer Kowa; NephroGenex
  • Class Antipsychotics; Picolines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic nephropathies

Highest Development Phases

  • Phase II Schizophrenia
  • Suspended Diabetic nephropathies
  • No development reported Acute kidney injury

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Acute kidney injury in USA (IV)
  • 24 Jun 2018 Biomarkers information updated
  • 23 Jan 2018 Phase-II clinical trials in Schizophrenia in Japan (unspecified) (Kowa pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top